Ibogaine case reports · cardiac outcomes
A focused guide to the documented cardiac findings reported alongside ibogaine and noribogaine: QT/QTc prolongation, arrhythmias, arrests, fatalities, and the limits of case-level attribution.
Case reports preserve important signals, but they do not establish a single cause in every event.
Published accounts of ibogaine-associated cardiac events vary greatly in what they document. Some include electrocardiograms, dose history, toxicology, co-ingestants, medical history, and post-mortem findings; others contain only a limited account of timing and outcome. This review stays close to that record rather than treating individual reports as proof of a uniform risk.
For the wider evidence and safety questions that frame this topic, the Iboquit evidence overview provides broader context for people researching Iboqu It. A useful baseline is that the QT interval represents ventricular electrical activity; long QT syndrome is associated with a higher susceptibility to dangerous ventricular rhythms, though a case report alone cannot determine why QT prolongation occurred in a particular person.
Three recurring record types
Across documented accounts, cardiac outcomes are best read as a sequence of reported observations: ECG changes, clinical events, contextual exposures, and—in fatal cases—available forensic evidence.
Reports may describe a prolonged QT or corrected QT interval after ibogaine exposure. QTc is used because heart rate affects the raw QT interval, but correction formulas themselves can produce different values. The recorded number, method, and timing matter when interpreting an individual account.
Case literature includes ventricular arrhythmias, including torsades de pointes, as well as cardiac arrest. Torsades de pointes is a distinctive polymorphic ventricular tachycardia that may occur in the setting of QT prolongation, as summarized by the NCBI clinical overview of torsades de pointes.
Fatality reports may contain toxicology and autopsy information, but completeness differs. Reported concentrations, other substances, organ findings, and preexisting disease can inform interpretation without resolving causation where the available record is incomplete.
Reading the documented record
Timing is central. A report may note symptoms, ECG changes, collapse, or hospital presentation in relation to dosing, but the interval may be imprecise. Ibogaine is metabolized to noribogaine, and reports that distinguish exposure timing from later findings can be more informative than those that do not.
Dose reporting is also uneven. Accounts may describe a stated amount, an estimated amount, repeated administration, a preparation of uncertain composition, or no reliable dose at all. Co-ingestants—including substances that may affect cardiac rhythm or metabolism—are important contextual facts, not incidental details. Preexisting cardiac history, electrolyte disturbance, and other physiologic factors may also be reported, or may be absent from the record.
Pharmacologic context
Proposed mechanisms are generally discussed as biologic plausibility, not as a way to assign certainty to an individual cardiac event. Ibogaine and noribogaine have distinct pharmacologic profiles, and case reports rarely supply the controlled evidence needed to isolate their effects in a person.
Experimental work has described effects of ibogaine on cardiac ion channels, including hERG-related potassium current, a pathway commonly considered in discussions of drug-related QT prolongation. The FDA’s cardiac safety context for drug development reflects why repolarization findings receive careful attention, while not making a case report a controlled safety study.
Noribogaine is a metabolite of ibogaine and may persist after the parent compound is no longer dominant. Its potential channel effects are therefore relevant when accounts describe delayed ECG changes or later rhythm events, but the available clinical details and toxicology in each report still set the limits of interpretation.
Cardiac events can have more than one contributing factor. A thoughtful reading separates the observed outcome from the proposed mechanism and from the incomplete circumstances around exposure. The site’s guidance on interpreting evidence limits explains why those distinctions matter when records are sparse.
A careful conclusion
Case reports support the conclusion that serious cardiac outcomes, including QT/QTc prolongation, torsades de pointes, cardiac arrest, and fatalities, have been documented in temporal association with ibogaine exposure. They also show why contextual details—dose, timing, co-ingestants, medical history, ECGs, and forensic findings—cannot be treated as optional.
They do not provide a clean denominator, a uniform exposure measure, or a reliable estimate of how often any outcome occurs. They cannot consistently distinguish ibogaine, noribogaine, co-exposures, underlying conditions, and unrecorded circumstances as causes in a single event. For an account of how Iboquit handles source scope and uncertainty, see the resource’s evidence principles.
Record before conclusion
Keep reported findings, proposed mechanisms, and unanswered questions distinct.